Please login to the form below

Not currently logged in
Email:
Password:

fasinumab

This page shows the latest fasinumab news and features for those working in and with pharma, biotech and healthcare.

FDA fast-tracks Pfizer and Lilly's tanezumab

FDA fast-tracks Pfizer and Lilly's tanezumab

a setback last October when their candidate fasinumab was placed under a clinical hold by the FDA, prompted by a case of joint destruction in its phase IIb trial.

Latest news

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    4, 325. Regeneron / Teva. Licence. Fasinumab in P3 for osteoarthritis pain, upfront payment $250m [excludes rights to Japan, Korea and other Asian markets].

  • Deal Watch October 2015 Deal Watch October 2015

    Collaboration, option to license. 339. Regeneron Pharmaceuticals/ Mitsubishi Tanabe Pharma. Fasinumab (REGN475), nerve growth factor mAb for musculoskeletal pain (p2b).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics